Which is more relevant for allo-HSCT outcome: cytogenetic risk or MRD status?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Arnon Nagler, Vice Chair of the Acute Leukaemia Working Party of the EBMT. We asked, Which is more relevant for allo-HSCT outcome: cytogenetic risk or MRD status?

In this video, Arnon Nagler talks about the role of measurable residual disease (MRD) compared with cytogenetic risk in allogeneic hematopoietic stem cell transplant (allo-HSCT) in patients with AML. Traditionally, leukemic risk defined the prognosis of AML, which was in turn determined by the presence of cytogenetic lesions. However, in recent years, MRD has become increasingly important.